Last reviewed · How we verify

NCT03505957

A Feasibility Study Evaluating the Use of SafeBreak Vascular in the Geriatric Trauma Population

Completed NA Last updated 5 March 2020
What this trial tests

NA trial testing SafeBreak Vascular in IV Dislodgement in 40 participants. Completed in 23 September 2018.

Timeline
7 May 2018
Primary endpoint
23 September 2018
23 September 2018

Quick facts

Lead sponsorLineus Medical
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment40
Start date7 May 2018
Primary completion23 September 2018
Estimated completion23 September 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Lineus Medical

Who can join

55 and older, any sex, with IV Dislodgement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SafeBreak Vascular is a medical device indicated for fluid flow control during the administration of IV fluids/medication to the patient's vascular system and to aid in the prevention of unintended disruption and dislodgment of IVs. SafeBreak Vascular may be used for any hospitalized patient with gravity tubing or IV pumps, for intermittent infusion or continuous infusion.The primary objective of this study is to determine if the delivery of IV medications and/or fluids with SafeBreak Vascular functions with the same reliability as current standard IV tubing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of SafeBreak Vascular

Trials testing the same drug.

Other Lineus Medical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03505957.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing